Do Institutional Investors Hate Iridex Corp (NASDAQ:IRIX)?

July 14, 2018 - By Mary Gaskins

IRIDEX Corporation (NASDAQ:IRIX) Logo

Sentiment for Iridex Corp (NASDAQ:IRIX)

Iridex Corp (NASDAQ:IRIX) institutional sentiment decreased to 0.7 in 2018 Q1. Its down -0.50, from 1.2 in 2017Q4. The ratio turned negative, as 7 investment managers increased or opened new stock positions, while 10 sold and decreased stock positions in Iridex Corp. The investment managers in our partner’s database reported: 5.59 million shares, up from 5.52 million shares in 2017Q4. Also, the number of investment managers holding Iridex Corp in their top 10 stock positions was flat from 1 to 1 for the same number . Sold All: 1 Reduced: 9 Increased: 5 New Position: 2.

IRIDEX Corporation provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company has market cap of $75.65 million. The firm offers laser consoles, such as Cyclo G6 laser system used for the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. It currently has negative earnings. It also provides delivery devices, including TxCell scanning laser delivery system that allows the physicians to perform multi-spot pattern scanning; Slit Lamp Adapter, which allows the physicians to utilize a standard slit lamp in diagnosis and treatment procedures; and TruFocus laser indirect ophthalmoscopes for use in procedures to treat peripheral retinal disorders.

The stock increased 4.67% or $0.29 during the last trading session, reaching $6.5. About 8,707 shares traded. IRIDEX Corporation (NASDAQ:IRIX) has declined 20.94% since July 14, 2017 and is downtrending. It has underperformed by 33.51% the S&P500.

Analysts await IRIDEX Corporation (NASDAQ:IRIX) to report earnings on August, 2. They expect $-0.32 EPS, down 33.33 % or $0.08 from last year’s $-0.24 per share. After $-0.31 actual EPS reported by IRIDEX Corporation for the previous quarter, Wall Street now forecasts 3.23 % negative EPS growth.

Paragon Associates & Paragon Associates Ii Joint Venture holds 10.42% of its portfolio in IRIDEX Corporation for 1.25 million shares. Acuta Capital Partners Llc owns 2.00 million shares or 1.87% of their US portfolio. Moreover, Lyon Street Capital Llc has 0.89% invested in the company for 483,760 shares. The Minnesota-based First Light Asset Management Llc has invested 0.49% in the stock. Perkins Capital Management Inc, a Minnesota-based fund reported 58,450 shares.

Since January 1, 0001, it had 0 insider purchases, and 1 insider sale for $16,444 activity.

More news for IRIDEX Corporation (NASDAQ:IRIX) were recently published by: Streetinsider.com, which released: “Iridex Corp (IRIX) Announces Approval of CYCLO G6 Glaucoma Laser System in Korea” on June 19, 2018. Globenewswire.com‘s article titled: “IRIDEX Reaches Milestone of 1000th Cyclo G6 System Shipped” and published on July 10, 2018 is yet another important article.

IRIDEX Corporation (NASDAQ:IRIX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.